title: [The impact of telmisartan on angiotensin converting enzyme 2 mRNA expression in monocyte-derived macrophages of diabetic hypertensive patients].
abstract: OBJECTIVE
  To investigate the effects of telmisartan on the expression of angiotensin converting enzyme 2 (ACE2) mRNA in monocyte-derived macrophages of hypertensive patients accompanied with diabetes.
  
  
  METHODS
  62 essential hypertensive patients accompanied with diabetes were randomly divided into two groups: regular treatment group, and telmisartan group. Then the content of ACE and ACE2 in serum was detected by ELISA, and the expression of ACE mRNA and ACE2 mRNA in monocyte-derived macrophages of patients was detected by RT-PCR before and after having been treated.
  
  
  RESULTS
  (1) After having been treated for 4 weeks and 12 weeks, the blood pressure of the patients in two groups were decreased significantly, Comparing with regular group, telmisartan group seemed to have more obvious therapeutic effect (P < 0.05); (2) After having been treated for 12 weeks, glycosylated hemoglobin diseased in both group, but there was no significant difference between the two group (P > 0.05); (3) In telmisartan group, the content of ACE2 in serum was increased after having been treated for 12 weeks than that in regular treatment group, [(23.9 ± 8.2) U/L vs (16.3 ± 8.9) U/L, P < 0.05]; and the expression of ACE2 mRNA in monocyte-derived macrophages in telmisartan group was obviously increased after 12 weeks comparing with regular treatment group (0.73 ± 0.06 vs 0.51 ± 0.04, P < 0.01).
  
  
  CONCLUSIONS
  The role of telmisartan in decreasing blood pressure and it's advantage to the metabolism of glucose are partly related with the up-regulation of ACE2 mRNA.
authors.affiliation: Department of Cardiology, the Second Hospital of Xi'an Jiaotong University, Xi'an, China.
authors.forename: Yong-qin
authors.initials: YQ
authors.lastname: Li
authors.forename: Juan-juan
authors.initials: JJ
authors.lastname: Wu
authors.forename: Deng-feng
authors.initials: DF
authors.lastname: Gao
authors.forename: Yan-mei
authors.initials: YM
authors.lastname: Fan
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.forename: Xiao-jin
authors.initials: XJ
authors.lastname: Qin
mesh_terms: D000368:Aged; D000085962:Angiotensin-Converting Enzyme 2; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000201:enzymology*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000201:enzymology*; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics; D000077333:Telmisartan
chemical_list: D001562:Benzimidazoles; D001565:Benzoates; D012333:RNA, Messenger; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; D000085962:Angiotensin-Converting Enzyme 2; D000077333:Telmisartan